https://www.live-feeds.com/feed/why-the-fda-should-not-approve-an-ineffective-multicancer-screening-testContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/why-the-fda-should-not-approve-an-ineffective-multicancer-screening-testhttps://www.live-feeds.com/feed/why-the-fda-should-not-approve-an-ineffective-multicancer-screening-test#u112201Fri, 09 Oct 2026 13:32:12 +0000An FDA advisory committee supports approving Grail's multicancer screening test, despite opposition from a cancer screening researcher who argues the test is ineffective and that taxpayers should not fund it. Concurrently, blood tests capable of screening for over fifty forms of cancer are available in Houston and are being studied by OHSU researchers. Questions surrounding cancer screening efficacy persist as discussions grow about regulatory approval standards and patient utilization. Financial markets are also reacting, with biotech stocks related to cancer screening gaining attention